Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
GlobeNewswire
· 68% of patients treated with ELI-002 developed cytotoxic mKRAS-specific CD4+ T cells
· 84% of patients treated with..